Condition
Esophagus Cancer, Stage III
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Unknown2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04907643Not ApplicableRecruiting
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
NCT04648917Phase 3UnknownPrimary
GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC)
NCT03285906Phase 2UnknownPrimary
An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric
Showing all 3 trials